Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

286
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
286
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

125
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
125
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

850
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
850
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

196
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
196

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.

Seminars in arthritis and rheumatism·2026
Same author

Validity and reliability of hand-held dynamometry for proximal strength assessment in systemic sclerosis-associated myopathy.

Seminars in arthritis and rheumatism·2026
Same author

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

ACR open rheumatology·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Nature communications·2026
Same author

Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.

Arthritis care & research·2026

Related Experiment Video

Updated: Dec 28, 2025

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.4K

Inflammatory muscle disease - An update.

Sara Baig1, Julie J Paik2

  • 1Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Suite 1B.1, Baltimore, MD 21224 USA.

Best Practice & Research. Clinical Rheumatology
|February 13, 2020
PubMed
Summary
This summary is machine-generated.

Idiopathic inflammatory myopathies (IIM) are complex autoimmune muscle diseases. This review covers updated classification criteria, new clinical phenotypes, outcome measures, and emerging treatments for IIM.

Keywords:
DermatomyositisImmune mediated myopathyInclusion body myositisMyositisPolymyositis

More Related Videos

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.4K
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.5K

Related Experiment Videos

Last Updated: Dec 28, 2025

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.4K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.4K
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.5K

Area of Science:

  • Rheumatology
  • Neurology
  • Immunology

Background:

  • Idiopathic inflammatory myopathies (IIM) encompass diverse autoimmune muscle diseases.
  • Subgroups include dermatomyositis, polymyositis, inclusion body myositis, and immune-mediated necrotizing myopathy.
  • Antisynthetase syndrome is recognized for perifascicular necrosis.

Purpose of the Study:

  • To review updated European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM.
  • To discuss newly identified clinical phenotypes linked to myositis autoantibodies.
  • To highlight advancements in outcome measurement and novel therapeutics for myositis.

Main Methods:

  • Literature review of recent advancements in IIM classification, clinical phenotypes, and treatment.
  • Analysis of updated diagnostic criteria and their limitations.
  • Evaluation of emerging therapeutic strategies and outcome assessment tools.

Main Results:

  • Updated EULAR/ACR criteria improve IIM diagnosis but have limitations in autoantibody utilization.
  • Novel clinical phenotypes associated with specific autoantibodies are emerging.
  • Scarcity of validated outcome measures challenges clinical trial interpretation and patient management.

Conclusions:

  • Refined classification criteria enhance IIM diagnosis, yet autoantibody specificity requires further integration.
  • Understanding diverse clinical phenotypes is crucial for targeted therapy.
  • Development of validated outcome measures is essential for evaluating novel IIM treatments.